



# GMA Field Medical Center of Excellence

---

LEARN. ENGAGE. SUCCEED.

# GLOBAL SCIENTIFIC TRAINING

Oncology Learning Frameworks





# INTRODUCTION

Throughout the Oncology Learning Framework, you will encounter the icons below to help you easily identify status of the learning asset and type of training.

While training modules are mandatory and serve as your foundational learning, updated content will frequently appear in the other types of training that reflect the newest data and congress updates. Please check back regularly to interact with new content as it is updated by Global Scientific Training. You will see New Content listed at the top of each training type, followed by those Mandatory items and finishing with anything Optional.

## STATUS ICONS (3)

Mandatory	Optional	New Content

## TRAINING TYPE ICONS (5)

Training Modules	Recordings	Additional Resources	Congress Training	Annotated Publications

## GETTING STARTED

Prior to beginning, assess what training you have recently completed and where you might need to refresh your knowledge. An alignment conversation on your training development plan with your manager is recommended before launching into the curriculum.

**Step 1:** Complete the General Oncology Frameworks

**Step 2:** Complete the Biomarker Framework


**Step 3:** Complete the Pan Tumor KEYTRUDA Framework

**Step 4:** Select your Tumor Area from the Navigation page to access and complete the specific Tumor Area Framework






## Suggested Learning Flow



Training Modules 
<a href="#">Intro to Oncology Foundational Module</a> 
<a href="#">Oncology Diagnostics &amp; Treatment Foundational Module</a> 
<a href="#">Introduction to Immunology</a> 
<a href="#">Cancer Immuno-editing Foundational Module</a> 
<a href="#">Tumor Microenvironment</a> 
<a href="#">Immune Checkpoints</a> 
<a href="#">Understanding Oncology Clinical Trials</a> 
<a href="#">OTSP 2020 Concept Summary</a> 
<a href="#">OTSP 2020 Areas of Interest Global Training</a> 

Recordings 
<a href="#">OTSP 2020 Areas Of Interest Global Training</a> 
<a href="#">OTSP 2020 Concept Summary Form</a> 
<i>Coming Soon!</i> Biostatistics Training










Additional Resources 
<a href="#">Slides – OTSP 2020 Areas of Interest Training</a> 
<a href="#">Form – OTSP 2020 Concept Summary Form</a> 
<i>Coming Soon!</i> Biostatistics Infographic












## Suggested Learning Flow





Training Modules 
<a href="#">Biomarker – Tumor Microenvironment</a> 
<a href="#">Overview of IO Biomarkers Foundational Module</a> 
<a href="#">Comparison of PD-L1 CPS and SP142 IC scoring methods</a> 
<a href="#">Biomarker – RNA Seq Training</a> 
<a href="#">Biomarkers – DNA Damage Response (DDR) Training</a> 
<a href="#">Biomarkers – TMB Global Training 2019</a> 
<a href="#">Non-traditional methods for genetic counseling</a> 
<a href="#">Supplemental Info: HRR and Genomic Testing Training</a> 

Recordings 
<a href="#">Biomarker – KN 158</a> 
<a href="#">KN158 with Scott Pruitt and Milayna Subar</a> 
<a href="#">Biomarker iSeminar Tumor Microenvironment</a> 
<a href="#">Comparison of PD-L1 CPS and SP142 IC scoring methods</a> 
<a href="#">iSeminar Exploratory Biomarkers: RNA – Seq</a> 
<a href="#">Biomarkers – DDR</a> 
<a href="#">Biomarkers-PDL1 CPS Pembrolizumab Monotherapy</a> 
<a href="#">Pre-ESMO 2019 Training – MSI-H and TMB</a> 
<a href="#">Non-traditional methods for genetic counseling</a> 

Congress Updates 
<a href="#">Pre-ESMO 2019 Training – MSI-H and TMB (Slides)</a> 


Annotated Publications 
<a href="#">Biomarker – KEYNOTE 158</a> 









Additional Resources 
<a href="#">Biomarker Clinical Trials Tracker Merck &amp; Competitors</a> 
















## Suggested Learning Flow



Training Modules 
<a href="#">Overview of the History of KEYTRUDA Foundational Module</a> 
<a href="#">History of Pembrolizumab</a> 
<a href="#">KEYTRUDA 400mg Q6W Dosing Internal Training</a> 
<a href="#">Molecular Attributes of Pembrolizumab</a> 
<a href="#">Pembrolizumab MOA</a> 
<a href="#">Diagnosis and Mechanisms of imAE's – Dr. Naidoo</a> 
<a href="#">Management of imAEs – Dr. Evan Lipson</a> 






Recordings 
<a href="#">Identifying-managing AEs with Immune Checkpoint Inhibitors</a> 
<a href="#">Molecular Attributes of Pembrolizumab</a> 
<a href="#">Identifying-managing AEs with checkpoint inhibitors</a> 
<a href="#">Management of imAEs – Dr. Evan Lipson</a> 
<a href="#">KEYTRUDA 400mg Q6W Dosing Background Training</a> 
<a href="#">Diagnosis and Mechanisms of imAEs with Dr. Naidoo</a> 
<a href="#">Pembrolizumab 400 mg Q 6 Weekly Dosing Update Podcast</a> 






Annotated Publications 
<a href="#">Pan-Tumor vanVugt, M. Jnl Immunother of Ca Aug 2019</a> 
<a href="#">Pan-Tumor – KN158 – Diaz et al</a> 







# TUMOR TYPE MENU

Select a Tumor Type Icon to Access each Framework

Thoracic		GU		
NSCLC	SCLC	PROSTATE	UROTHELIAL	RCC
				

<u>GI ALL TUMORS – Start HERE</u>				
HBC	ESOPHAGEAL	MSI-H/CRC	GASTRIC	PANCREATIC
				

WOMEN'S CANCERS			
Ovarian	Breast	Endometrial	Cervical
			

Other		
HN	Heme	Melanoma
		



## Suggested Learning Flow



Training Modules
<a href="#">NSCLC Foundational Module</a>
<b>Coming Soon!</b> NSCLC Expert Module

Congress Updates
<a href="#">ASCO 2019 Post Congress Debrief (slides)</a>
<a href="#">Benefit of IO Upfront Part II updates from AACR ELCC ASCO</a>
<a href="#">Post ESMO IO Congress Debrief (slides)</a>
<a href="#">Post WCLC 2019 Training – CORE (slides)</a>
<a href="#">Post WCLC 2019 Session 1 CORE (slides)</a>
<a href="#">Post WCLC ESMO 2019 Congress Debrief 10-15-19 (slides)</a>
<a href="#">Post WCLC ESMO 2019 Highlight on PD-L1 and TMB Biomarkers 11-6-19 (slides)</a>

Annotated Publications
<a href="#">AP- Lung Cancer KN-042</a>
<b>Coming Soon!</b> AP – Lung Cancer KN-010 LTO & Retreatment

Additional Resources
<a href="#">CTT - Lung - NSCLC KEYNOTE and Competitor</a>
<a href="#">ONLINE Resource CME- NCCN</a>





Recordings
<a href="#">KRAS in NSCLC – Ellie Corigliano</a>
<a href="#">Immunotherapy in 1L NSCLC – the benefit of IO</a>
<a href="#">Insights into CM227 – W. Mondeshire</a>
<a href="#">Pembro-IO in 1L NSCLC – the benefit of IO Upfront Part 2</a>
<a href="#">Pre ASCO 2019 Congress</a>
<a href="#">ASCO 2019 Post Congress Debrief</a>
<a href="#">Pre ESMO 2019 Congress Training</a>
<a href="#">Post ESMO IO 2019 Congress Debrief</a>
<a href="#">Post ESMO IO 2019 Congress Debrief – Part 1 KEYNOTE</a>
<a href="#">Publication team Highlight &amp; WCLC Intro</a>
<a href="#">Pre WCLC 2019 CORE Data</a>
<a href="#">Pre WCLC 2019 KEYNOTE and Competitor Data</a>
<a href="#">CORE at WCLC 2019 – Tom Burke</a>
<a href="#">WCLC 2019 – Thoracic Malignancies – B. Piperdi &amp; C. Pietanza</a>
<a href="#">WCLC 2019 – Thoracic Malignancies – M. Maradeo data rvw</a>
<a href="#">Post WCLC ESMO Highlights on PD-L1 and TMB Biomarkers</a>
<a href="#">Post WCLC 2019 Congress Debrief – CORE</a>
<a href="#">Post WCLC ESMO Highlights on TMB</a>
<a href="#">Post WCLC ESMO 2019 Congress Debrief</a>
<b>Coming Soon!</b> NSCLC Video










## Suggested Learning Flow



Training Modules 
<a href="#">SCLC Disease State Foundational Module</a> 
<a href="#">SCLC Expert Module</a> 
<a href="#">SCLC - Is the clinical landscape changing_Pietanza</a> 

Recordings 
<a href="#">SCLC - Is the Clinical Landscape Changing?</a> 
<a href="#">Post WCLC ESMO 2019 Congress Debrief</a> 

Congress Updates 
<a href="#">Post WCLC ESMO 2019 Congress Debrief 10-15-19 (slides)</a> 


Additional Resources 
<a href="#">CTT - Lung - SCLC - KEYNOTE and Competitor</a> 





# General GI Tumors Learning Framework

## Suggested Learning Flow





**Note: Training in this General GI Tumors Framework serves as the backdrop for Tumor Type specific training. Be sure to access each tumor type for foundational required training.**







### Training Modules

Foundational & Expert Modules are found in tumor type frameworks



### Congress Updates

<a href="#">Pre-ESMO 2019 GI Training – CORE: PRO/QOL (Slides)</a>	
<a href="#">Pre-ASCO GI 2020 Training: Pembrolizumab and Competitor Data Overview (Slides)</a>	
<a href="#">ASCO – GI 2020 On Demand (Slides)</a>	
<a href="#">Post – ESMO – Asia 2019 (Slides)</a>	
<a href="#">Post-ESMO 2019 GI Debrief: Competitors (Slides)</a>	
<a href="#">Post-ESMO 2019 GI Debrief: Pembrolizumab (Slides)</a>	
<a href="#">Pre-ASCO 2019 GI Training (Slides)</a>	
<a href="#">Post-ASCO 2019 Training Debrief (Slides)</a>	

### Recordings

<a href="#">GEN Alpha Allocation Biostatistics Training</a>	
<a href="#">Pre-ASCO GI 2020 Training: Pembrolizumab &amp; Competitor Data Overview (recording)</a>	
<a href="#">Post-ASCO 2019 Training Debrief (recording)</a>	
<a href="#">Pre-ESMO 2019 GI Training – CORE: PRO/QOL (recording)</a>	
<a href="#">Post-ESMO 2019 GI Debrief: Competitors (recording)</a>	
<a href="#">Post-ESMO 2019 GI Debrief: Pembrolizumab (recording)</a>	


### Additional Resources




<a href="#">GEN Alpha Allocation in Late-Stage IO Trials (slides)</a>	
<a href="#">Podcast – GI – Biomarkers in GI</a>	













## Suggested Learning Flow





Training Modules 
<b>Coming Soon!</b> Overview of HCC Foundational Module
<b>Coming Soon!</b> Management of HCC Foundational Module
<b>Coming Soon!</b> Competitive Landscape in HCC Foundational Module
<b>Coming Soon!</b> HCC Expert Clinical Module
<b>Coming Soon!</b> Overview of Biliary Cancer Foundational Module
<a href="#">Clinical Immersion – HCC Disease State Overview</a> 
<a href="#">Clinical Immersion – Rule of Immunotherapy in HCC</a> 
<a href="#">Clinical Immersion – Trends in TACE</a> 
<a href="#">Clinical Immersion – TX Sequencing – Surgery to Systemic Therapy</a> 

Congress Updates 
<a href="#">KN-240 JiT – ASCO 2019 (slides)</a> 
<a href="#">ASCO – GI 2020 On Demand (Slides)</a> 
<b>**Note:</b> Congress updates may also be included in the General GI All Tumors Framework

Recordings 
<b>Coming Soon!</b> Recording - GI-HCC Overview, Treatment Landscape and Clinical Data
<a href="#">Post-ESMO-Asia 2019 Debrief – IMBRAVE 150</a> 
<a href="#">On-Demand Recording – IMBRAVE 150</a> 
<a href="#">On-Demand Results from Checkmate 040 – NIVO + IPI + CABO</a> 
<a href="#">On-Demand KN-743 REG+PEMBRO for 1L Treatment of adv HCC</a> 


Annotated Publications 
<a href="#">Annotated Publication - HCC - KN-240</a> 






Additional Resources 
<b>Coming Soon!</b> GI-HCC Overview, Treatment Landscape, and Clinical Data (Slides)
<a href="#">Clinical Trials Library – GI – HCC- Pembrolizumab</a> 





## Suggested Learning Flow






Training Modules 
<a href="#">Esophageal Cancer Disease State</a> 
<b>Coming Soon!</b> Esophageal Expert Module
<a href="#">Clinical Immersion – Overview of Esophageal Cancer</a> 
<a href="#">Clinical Immersion – Esophageal Treatment Journey</a> 
<a href="#">Clinical Immersion – Immunotherapy in Esophageal</a> 

Congress Updates 	
<a href="#">Pre-ESMO 2019 Training- Gastric, Esophageal, Pancreatic</a> 	
<a href="#">ASCO – GI 2020 On Demand (Slides)</a> 	
<b>**Note:</b> Congress updates may also be included in the General GI All Tumors Framework	

Recordings 
<a href="#">KN-181 Data Training Presentation</a> 
<a href="#">Pre-ESMO 2019 Training: Gastric, Esophageal, Pancreatic</a> 
<a href="#">On-Demand Phase III trial tislelizumab+cCRT and placebo+cCRT</a> 

Annotated Publications 
<b>Coming Soon!</b> KN-181 Annotated Publication (pending publication)

Additional Resources 
<a href="#">Quick Reference - Esophageal KN-181</a>  










# MSI-H/CRC Learning Framework

## Suggested Learning Flow



Training Modules 
<a href="#">Overview of MSI-H CRC Foundational Module</a> 
<b>Coming Soon!</b> Management of (MSI-H) CRC Foundational Module
<b>Coming Soon!</b> Competitive Landscape in (MSI-H) CRC Foundational
<b>Coming Soon!</b> CRC Expert Module

Recordings 
<a href="#">On-Demand Final results of the phase II AVETUX</a> 
<a href="#">On-Demand Nivolumab + LD ipilimumab Clinical Update – CM-142</a> 
<a href="#">On-Demand Safety and efficacy of anti-PD1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers (GARNET)</a> 
<a href="#">Pre-ESMO 2019 Training – MSI-H and TMB</a> 
<b>Coming Soon!</b> KN-177 Protocol and CRC Training

Congress Updates 
<a href="#">Pre-ESMO 2019 Training – MSI-H and TMB (Slides)</a> 
<a href="#">ASCO – GI 2020 On Demand (Slides)</a> 
<b>**Note:</b> Congress updates may also be included in the General GI All Tumors Framework

Annotated Publications 
<a href="#">Annotated Publication – MSI-H CRC KN-164</a> 
<b>Coming Soon!</b> KN-177 Annotated Publication (pending publication)










# Gastric Learning Framework






## Suggested Learning Flow



Training Modules 
<a href="#">Overview of Gastric Cancer Foundational Module</a> 
<a href="#">Management of Gastric Cancer Foundational Module</a> 
<a href="#">Biomarker Testing in Gastric Cancer Foundational Module</a> 
<a href="#">Competitive Landscape in Gastric Cancer Foundational Module</a> 
<b>Coming Soon!</b> Gastric Expert Module

Recordings 
<a href="#">Pre-ESMO 2019 Training- Gastric, Esophageal, Pancreatic</a> 
<a href="#">On-Demand An interim safety analysis of the DANTE</a> 
<a href="#">On-Demand ATTRACTION-2 Three-yr. update</a> 
<a href="#">Results of JAVELIN Gastric 100 Phase 3 trial</a> 


Congress Updates 
<a href="#">Pre-ESMO 2019 Training- Gastric, Esophageal, Pancreatic</a> 
<a href="#">KN-062 JiT - ASCO 2019 (slides)</a> 
<a href="#">ASCO – GI 2020 On Demand (Slides)</a> 
<b>**Note:</b> Congress updates may also be included in the General GI All Tumors Framework










Additional Resources 
<a href="#">Quick Reference - Gastric KN-062</a>  
<a href="#">Clinical Trials Library – GI – Gastric and GEJ- Pembrolizumab</a>  























## Suggested Learning Flow



Training Modules 
<i>Coming Soon!</i> Pancreatic Foundational Module
<i>Coming Soon!</i> Pancreatic Expert Module
<a href="#">Background to Pancreatic Cancer (Foundational)</a> 
<a href="#">Management of Pancreatic Cancer (Foundational)</a> 
<a href="#">BRCA in Pancreatic Cancer (Foundational)</a> 
<a href="#">Olaparib in Pancreatic Approval USPI (Foundational)</a> 
<a href="#">POLO: an introduction to the study design (Foundational)</a> 
<a href="#">POLO Study Results - BRCAm Pancreatic (Foundational)</a> 
<a href="#">POLO Study Design &amp; PARPi Competitor Data (Foundational)</a> 
<a href="#">Pancreatic Disease State &amp; Treatment Landscape Foundational</a> 

Congress Updates 
<a href="#">AZ Post-ASCO 2019 Pancreatic Cancer (slides)</a> 
<a href="#">Pre-ESMO 2019 Training- Gastric, Esophageal, Pancreatic</a> 
<a href="#">ASCO – GI 2020 On Demand (Slides)</a> 

Recordings 
<a href="#">Olaparib in Pancreatic Approval USPI</a> 
<a href="#">POLO Study Design &amp; PARPi Competitor Data</a> 
<a href="#">AZ Post-ASCO 2019 Pancreatic Cancer Update</a> 
<a href="#">On-Demand HALO 109-301 – Phase 3 study of PEGPH20+AG</a> 
<a href="#">On-Demand PDAC-BRCA-PALB</a> 
<a href="#">Physician &amp; patient perspectives: pancreatic cancer disease state and impact of Olaparib</a> 
<a href="#">Physician &amp; patient perspectives: impact of POLO data and use of Olaparib across pancreatic, ovarian and breast cancer</a> 
<a href="#">POLO rationale, design, results &amp; conclusions: Dr. Hedy Kindler</a> 
<a href="#">Clinical perspective in pancreatic cancer: Dr. Hedy Kindler &amp; Dr. Talia Golan</a> 
<a href="#">History of molecular markers in pancreatic cancer and a look into the future: Dr. Talia Golan</a> 
<a href="#">Pancreatic Disease State Overview &amp; Treatment Landscape</a> 
<a href="#">Pre-ESMO 2019 Training: Gastric, Esophageal, Pancreatic</a> 

Additional Resources 
<a href="#">Quick Reference – Pancreatic POLO Study</a> 
<a href="#">Olaparib curricula tree with direct links</a> 



















































# Ovarian Learning Framework

## Suggested Learning Flow



Training Modules 	Recordings 	
<b>Coming Soon!</b> Ovarian Foundational Module	<a href="#">Ovarian – SGO Abstracts 2020 (PAOLO-1)</a> 	
<b>Coming Soon!</b> Ovarian Expert Module	<a href="#">HRR Deficiency and HRD Testing Post –ESMO 2019</a> 	
<a href="#">Background – Ovarian cancer</a> 	<a href="#">Olaparib in newly diagnosed ovarian cancer</a> 	
<a href="#">Management of Ovarian Cancer</a> 	<a href="#">Ovarian cancer-onsite medical training ASCO 2019 - P1</a> 	
<a href="#">BRCA in Ovarian Cancer</a> 	<a href="#">Ovarian cancer-onsite medical training ASCO 2019 - P2</a> 	
<a href="#">Deep Dive oncogenetics</a> 	<a href="#">Panel discussion and audience Q&amp;A EXMO 2019 (PAOLA-1)</a> 	
<a href="#">Bevacizumab Deep Dive</a> 	<a href="#">PAOLA-1, PRIMA &amp; VELIA – ESMO 2019 – P1</a> 	
<a href="#">PAOLA-1 Introduction</a> 	<a href="#">PAOLA-1, PRIMA &amp; VELIA – ESMO 2019 – P2</a> 	
<a href="#">PAOLA-1 Results</a> 	<a href="#">PAOLA-1, PRIMA &amp; VELIA – ESMO 2019– P3</a> 	
<a href="#">PRIMA in context</a> 	<a href="#">Pre-ESMO 2019 on demand</a> 	
<a href="#">PRIMA Overview – Niraparib</a> 	<a href="#">Post-ESMO 2019 Ovarian Cancer</a> 	
<a href="#">SOLO-1 introduction</a> 	<a href="#">Reactions to the PAOLA-1 data ESMO 2019</a> 	
<a href="#">SOLO-1 results</a> 	<a href="#">SOLO-1 introduction</a> 	
<a href="#">SOLO-2 introduction</a> 	<a href="#">SOLO-1 summary video</a> 	
<a href="#">SOLO-2 results - ovarian cancer</a> 	<a href="#">Tumor BRCA testing in Ovarian Cancer Dx</a> 	
<a href="#">SOLO-3 introduction- ovarian cancer</a> 	<a href="#">Post ASCO 2019 Ovarian Clinical Perspectives</a> 	
<a href="#">Tumor BRCA Testing in Ovarian Cancer</a> 	<b>Congress Updates</b> 	
<a href="#">Tumor BRCA Testing in Ovarian Cancer Q&amp;A</a> 	<a href="#">Post ASCO 2019 Ovarian Clinical Perspectives (slides)</a> 	
<a href="#">VEGF inhibitor combination in PSR Ovarian</a> 	<a href="#">SOLO-1 Results ESMO 2019 Update</a> 	
	<a href="#">PAOLA-1, PRIMA,VELIA data in context F2F Training ESMO 2019</a> 	
	<a href="#">Pre-ESMO 2019 on demand</a> 	
	<a href="#">Post-ESMO 2019 Ovarian</a> 	
	<a href="#">HRR Deficiency and HRD Testing Post – ESMO 2019</a> 	
	<a href="#">Other trials in Ovarian Cancer Post-ESMO 2019</a> 	
	<a href="#">SGO Abstracts 2020 (PAOLO-1)</a> 	
	<a href="#">SOLO-1 Results ASCO 2019 updates</a> 	
	<a href="#">SOLO-3 study results ASCO 2019</a> 	

### Additional Resources

[Clinical Trial Tracker – Ovarian Cancer](#) 


[Olaparib curricula tree with direct links](#)





















# Breast Learning Framework




## Suggested Learning Flow




Training Modules 
<a href="#">Breast Cancer Foundational Module</a> 
<b>Coming Soon!</b> Breast Cancer Expert Module
<a href="#">Breast Cancer Biomarker Landscape</a> 
<a href="#">Triple-Negative Breast Cancer Disease Overview</a> 
<a href="#">Triple-Negative Breast Cancer Treatment Overview</a> 
<a href="#">Neoadjuvant TNBC Training</a> 
<a href="#">Neoadjuvant Treatment for TNBC KN-522</a> 
<a href="#">Metastatic TNBC KN-119, KN-355</a> 
<a href="#">Breast Cancer On-going studies KEYLYNK-009 and KN-756</a> 
<a href="#">BRCA in Breast Cancer</a> 
<a href="#">Breast- EMBRACA deep dive</a> 
<a href="#">Breast- OlympiAD Introduction and Results</a> 

Recordings 
<a href="#">SABCS 2019 On-demand Recording</a> 
<a href="#">SABCS 2019 Post-Congress Debrief</a> 
<a href="#">Breast Cancer On-going Studies (KEYLYNK-009 and KN-756)</a> 
<a href="#">Breast Cancer Biomarker Landscape</a> 
<a href="#">Triple-Negative Breast Cancer Disease Overview</a> 
<a href="#">Triple-Negative Breast Cancer Treatment Overview</a> 
<a href="#">Women's Cancer – ESMO 2019 Post-Congress Training</a> 
<a href="#">ASCO 2019 Post-Congress Training – Women's Cancer</a> 

Annotated Publications 
<a href="#">Annotated Publication – Breast – KN-522</a> 

Congress Updates 
<a href="#">Breast - KN522 JiT ESMO 2019 (slides)</a> 
<a href="#">SABCS 2019 Post-Congress Debrief (slides)</a> 
<a href="#">SABCS 2019 Post-Congress On-demand (slides)</a> 
<a href="#">Women's Cancer –ESMO 2019 Post Congress Training (slides)</a> 
<a href="#">ASCO 2019 Post – Congress Training – Women's Cancer (slides)</a> 

Additional Resources 
<a href="#">Olaparib curricula tree with direct links</a>







## Suggested Learning Flow



### Training Modules

- [Endometrial Cancer Foundational Module](#) 
- [Endometrial Cancer Disease State & Treatment Landscape](#) 
- [Endometrial Cancer Foundational Module PDF – Open in ADOBE ACROBAT](#) 

### Recordings

- [Endometrial Cancer Disease State and Treatment Landscape](#) 
- [PODCAST: Biomarker KN-158](#) 
- [Women’s Cancer – ESMO 2019 Post-Congress Training](#) 
- [ASCO 2019 Post-Congress Training – Women’s Cancer](#) 

### Congress Updates

- [Women’s Cancer –ESMO 2019 Post Congress Training \(slides\)](#) 
- [ASCO 2019 Post – Congress Training – Women’s Cancer \(slides\)](#) 

### Annotated Publications

- [Annotated Publication – Biomarker KN-158](#) 

### Additional Resources

- [Clinical Trial Tracker – Endometrial Cancer](#) 
- [KN-146 Quick Reference](#) 
- [Levatinib in EC – Lancet article – Makker 2019](#) 





## Suggested Learning Flow



### Training Modules

*Coming Soon!* Cervical Foundational Module

[Cervical Rationale for IO Deck](#) 

### Recordings

[Women's Cancer – ESMO 2019 Post-Congress Training](#)

[ASCO 2019 Post-Congress Training – Women's Cancer](#)

### Congress Updates

[Women's Cancer –ESMO 2019 Post Congress Training \(slides\)](#) 

[ASCO 2019 Post – Congress Training – Women's Cancer \(slides\)](#) 

### Additional Resources

[Cervical Cancer Clinical Trial Tracker](#) 

[KN-158 Cervical Nutshell](#) 


[KN-158 Pembro efficacy and safety in cervical cancer](#) 





# Prostate Learning Framework

## Suggested Learning Flow



### Training Modules

- Coming Soon!** Prostate Foundational Module
- Coming Soon!** Prostate Expert Clinical Module w/ combo data

### Congress Updates

- [Post- ASCO GU 2020 On Demand Training \(slides\)](#) 🔑
- [ASCO GU 2020 Post-Congress On-demand \(slides\)](#) 🔑
- [Recording - Prostate - Post ASCO GU 2020 PARP inhibitors](#) 🔑
- [Recording - Prostate - Clinical Perspectives Post ASCO GU 2020](#) 🔑
- [ESMO 2019 GU Post-congress On-demand \(slides\)](#) ✕🗄
- [Post-ESMO 2019 10/16 webinar Drs. Morgans & Pezaro \(slides\)](#) ✕🗄
- [Prostate – PROfound F2F ESMO 2019 \(slides\)](#) ✕🗄
- [Post-ESMO 2019 GU Congress Training \(slides\)](#) ✕🗄

### Additional Resources

- [Slides - Prostate - NCCN Guidelines Update March 2020](#) 🔑
- [Prostate Clinical Immersion Day 1](#) ✕🗄
- [Prostate Clinical Immersion Day 2](#) ✕🗄
- [PROpel introduction](#) ✕🗄
- [PROpel: a deeper dive into eligibility criteria](#) ✕🗄
- [PROfound introduction](#) ✕🗄
- [PROfound Study Results and Conclusions](#) ✕🗄
- [PROfound TTT Patient Pathway and Case Management](#) ✕🗄
- [Olaparib curricula tree with direct links](#) ✕🗄

### Recordings

- [Recording - Prostate - NCCN Guidelines Update March 2020](#) 🔑
- [Recording - Prostate - PROfound Patient Reported Outcomes](#) 🔑
- [GSC Prostate ASCO](#) 🔑
- [KEYNOTE - 199, Cohorts 1-3 and 4-5 ASCO GU 2020](#) 🔑
- [KEYNOTE – 365 Cohort A ASCO GU 2020](#) 🔑
- [KEYNOTE – 365 Cohort B ASCO GU 2020](#) 🔑
- [KEYNOTE – 365 Cohort C ASCO GU 2020](#) 🔑
- [Diagnostics in PC - Dr. Tim French](#) ✕🗄
- [Imaging in Prostate Cancer – Dr. Koo](#) ✕🗄
- [Prostate Cancer & Treatment](#) ✕🗄
- [Biology of HRRm in Prostate Cancer with Dr. Joaquin Mateo](#) ✕🗄
- [PROfound NGS ASCO GU 2020](#) ✕🗄
- [PROfound Prior Taxane Use ASCP GU 2020](#) ✕🗄
- [TTT background to PROfound and PROpel study](#) ✕🗄
- [TTT results deep dive and panel](#) ✕🗄
- [TTT summary, impact and diagnostics and competitor](#) ✕🗄
- [Clinical perspectives in prostate cancer and molecular Dx](#) ✕🗄
- [Clinical perspectives in prostate cancer and PARPi therapy](#) ✕🗄
- [Clinical perspectives in prostate cancer and treatment](#) ✕🗄

### Annotated Publications


- [Study 8 annotated paper](#) ✕🗄
- Coming Soon!** PROfound Annotated Publication














# Urothelial Learning Framework















## Suggested Learning Flow



Training Modules 
<a href="#">Urothelial Foundational Module</a> 
<a href="#">Urothelial Expert Module</a> 

Congress Updates 
<a href="#">ASCO GU 2020 NMIBC Training (slides)</a> 
<a href="#">Post- ASCO GU 2020 On Demand Training (slides)</a> 
<a href="#">ASCO GU 2020 Post-Congress On-demand (slides)</a> 
<a href="#">Post-ESMO 2019 GU Congress Training (slides)</a> 
<a href="#">ESMO 2019 GU Post-congress On-demand</a> 
<a href="#">ESMO 2019 GU IMVigor130 Training (slides)</a> 


Additional Resources 
<a href="#">Bladder Clinical Trial Tracker</a> 
<a href="#">Post BCG Intravesical Chemo Data</a> 
<a href="#">GU – Dinney CP Adstiladrin</a> 
<a href="#">NMIBC Classification of BCG Failure</a> 
<a href="#">Emerging Therapies in BCG- Unresponsive NMIBC</a> 

Recordings 
<a href="#">Adstiladrin ASCO GU 2020</a> 
<a href="#">ASCO GU 2020 NMIBC Training – Dr. Steinberg</a> 
<a href="#">GSC RCC &amp; Bladder Resources ASCO GU 2020</a> 
<a href="#">BLASST-1 ASCO GU 2020</a> 
<a href="#">EV-103 ASCO GU 2020</a> 
<a href="#">IMVigor 130 ASCO GU 2020</a> 
<a href="#">FORT – 1 ASCO GU 2020</a> 
<a href="#">NIMBUS ASCO GU 2020</a> 
<a href="#">ASCO GU 2019 – NMIBC Training – Dr. Kamat</a> 
<a href="#">Dr. Kamat NMIBC Training ASCO</a> 
<a href="#">ESMO 2019 GU IMVigor</a> 
<a href="#">SAUL Study Short Recording</a> 
<a href="#">KN-045 FUP ESMO 2019</a> 









## Suggested Learning Flow



### Training Modules

<a href="#">Overview of RCC Foundational Module</a> 
<a href="#">RCC Disease State Foundational Deck</a> 
<a href="#">Management of RCC Foundational Module</a> 
<a href="#">Competitive Landscape in RCC Foundational Module</a> 
<b>Coming Soon!</b> RCC Patient Journey Supplement
<b>Coming Soon!</b> RCC Expert Module

### Congress Updates

<a href="#">HIF2A Medical Training at ASCO (slides)</a> 
<a href="#">Post- ASCO GU 2020 On Demand Training (slides)</a> 
<a href="#">ASCO GU 2020 Post-Congress On-demand</a> 
<a href="#">ESMO 2019 GU Post-congress On-demand</a>  
<a href="#">Post-ESMO 2019 GU Congress Training (slides)</a>  


























### Annotated Publications

<a href="#">Merck KN-426 Annotated</a>  

### Additional Resources

<a href="#">RCC Clinical Trial Tracker</a> 

### Recordings


<a href="#">HIF2A Training at ASCO</a> 
<a href="#">KN-426 EU Label &amp; Data</a> 
<a href="#">CM-025 ASCO GU2020</a> 
<a href="#">CM-214 ASCO GU2020</a> 
<a href="#">HIF – 2a MK6482</a> 
<a href="#">KEYNOTE-427 ASCO GU2020</a> 
<a href="#">KN-146 BMx ASCO GU2020</a> 
<a href="#">MK-6482 ASCO GU2020</a> 
<a href="#">Nivolumab (ASCe Study) ASCO GU2020</a> 
<a href="#">RADVAX ASCO GU2020</a> 
<a href="#">Study 221 ASCO GU2020</a> 
<a href="#">Classification of BCG Failure</a>  
<a href="#">CM-214 DepOR ESMO 2019</a>  
<a href="#">CM-214 QoL ESMO 2019</a>  
<a href="#">JAVELIN DepOR analysis ASCO GU2020</a>  
<a href="#">KN-427A and B ESMO 2019</a>  
<a href="#">NIVES ASCO GU2020</a>  
<a href="#">TITAN RCC ESMO 2019</a>  


























# Head & Neck Learning Framework




## Suggested Learning Flow



Training Modules 
<a href="#">Overview of HNSCC Foundational Module</a> 
<a href="#">Management of HNSCC Foundational Module</a> 
<a href="#">Competitive Landscape in HNSCC Foundational Module</a> 
<a href="#">Biomarker Testing in HNSCC Foundational Module</a> 
<a href="#">1L Recurrent Metastatic HNSCC PD-L1 Biomarker rationale (slides)</a>  
<a href="#">KEYNOTE-048 Statistics Training Slides</a>  
<a href="#">cSCC Disease State Training (slides)</a>  
<a href="#">CheckMate141-Data Review (Including Platinum-refractory Subgroup)</a>  
<b>Coming Soon!</b> HNSCC Patient Journey Foundational Module
<b>Coming Soon!</b> HNSCC Expert Module

Recordings 
<a href="#">1L Recurrent Metastatic HNSCC PD-L2 Biomarker rationale</a> 
<a href="#">KN-048 Statistics</a> 
<a href="#">HNSCC Pembrolizumab Post-ASCO 2018</a> 
<a href="#">HNSCC ASCO 2019 Post Congress Debrief</a> 
<a href="#">HNSCC Pembrolizumab Post-ASCO 2018</a> 
<a href="#">Post ESMO 2019 HNSCC Training Debrief</a> 
<a href="#">CheckMate-141 Data Review (Including Platinum-refractory Subgroup)</a> 


Congress Updates 
<a href="#">HNSCC Pembrolizumab Post-ASCO 2018</a>  
<a href="#">Post-ASCO 2019 HNSCC Training Debrief (slides)</a>  
<a href="#">Post ESMO 2019 Merck and Competitor Key Data Debrief</a>  






Additional Resources 
<a href="#">Clinical Trial Library-HNSCC-Merck Clinical Trials</a>  












## Suggested Learning Flow



Training Modules 
<a href="#">Overview of Melanoma Foundational Module</a> 
<a href="#">Management of Melanoma Foundational Module</a> 
<a href="#">Competitive Landscape in Melanoma Foundational Module</a> 
<a href="#">Biomarker Testing In Melanoma Foundational Module</a> 
<b>Coming Soon!</b> Melanoma Expert Module

Recordings 
<a href="#">Post ASCO 2019 Melanoma Training</a> 
<a href="#">Melanoma and HNSCC - Post-ESMO 2019 Congress Debrief</a> 
<a href="#">Melanoma Post-SITCSMR 2019 Competitor Data Debrief</a> 
<a href="#">Post SITC and SMR 2019 Congress Debrief Merck Data Debrief</a> 

Congress Updates 
<a href="#">Melanoma ASCO 2019 Pre-congress Training</a> 
<a href="#">Melanoma and HNSCC - Post ESMO 2019 Congress Debrief (slides)</a> 
<a href="#">Post SITC &amp; SMR 2019 Congress Debrief Competitor Data (slides)</a> 
<a href="#">Post SITC &amp; SMR 2019 Congress Debrief Merck Data (slides)</a>

Additional Resources 
<a href="#">Clinical Trial Library-Melanoma Merck Clinical Trials</a> 





## Suggested Learning Flow



Foundational  
Module



Expert  
Module



Clinical Trial  
Trackers



Congress  
Updates

### Training Modules



### Recordings



### Additional Resources



### Annotated Publications



### Congress Updates



COMING SOON